Phase 1 Study of Every Other Week Anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Monoclonal Antibody IMC-1121B [ramucirumab; ImClone Systems] in Patients With Advanced Solid Tumors Who Have Not Responded To Standard Therapy
Phase of Trial: Phase I
Latest Information Update: 18 Mar 2015
At a glance
- Drugs Ramucirumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors ImClone Systems
- 24 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Sep 2009 Planned end date changed from 1 Dec 2009 to 1 Jan 2010 as reported by ClinicalTrials.gov
- 05 Nov 2008 New source identified and integrated (ClinicalTrials.gov record NCT00786383).